KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Invested Capital (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Return on Invested Capital data on record, last reported at 0.59% in Q3 2025.

  • For Q3 2025, Return on Invested Capital fell 141.0% year-over-year to 0.59%; the TTM value through Sep 2025 reached 0.59%, down 141.0%, while the annual FY2024 figure was 0.26%, 3.0% down from the prior year.
  • Return on Invested Capital reached 0.59% in Q3 2025 per NKTR's latest filing, down from 3.92% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 3.92% in Q2 2025 and bottomed at 0.92% in Q1 2025.
  • Average Return on Invested Capital over 5 years is 0.03%, with a median of 0.23% recorded in 2022.
  • The widest YoY moves for Return on Invested Capital: up 351bps in 2025, down -141bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.15% in 2021, then tumbled by -34bps to 0.2% in 2022, then tumbled by -101bps to 0.4% in 2023, then decreased by -14bps to 0.46% in 2024, then decreased by -29bps to 0.59% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.59% in Q3 2025, 3.92% in Q2 2025, and 0.92% in Q1 2025.